logo-loader

ReNeuron presents more data on potential for its Exosome therapy as cancer treatment

Published: 07:36 09 Oct 2017 BST

picture of cell
Exosomes are nano-sized particles in the bloodstream and other body fluids

ReNeuron Group PLC (LON:RENE) is to present more pre-clinical data highlighting the potential of its exosome therapy as a cancer treatment.

Data will show a significant reduction in cancer cell proliferation when treated with ExoPr0 and provides important proof-of-concept for applications across a range of cancers, ReNeuron said in a statement.

READ: ReNeuron Group's therapeutic programme progressing to plan

Dr Randolph Corteling, head of research at ReNeuron, added the data built upon data presented earlier this year relating to the characterisation and scale-up potential of ExoPr0 and the ability to deliver ExoPr0 by local or systemic administration to target specific organs. 

“Taken together, this already substantial body of pre-clinical evidence clearly demonstrates the potential of this novel therapeutic platform to target multiple diseases, including cancer."

Professor Karol Sikora, a leading UK-based oncologist and an adviser to ReNeuron, added: "This is a novel and completely unexplored strategy for selectively targeting the growth of cancer cells.

“This work has the potential to uncover a whole new area in cancer therapeutics."

WATCH: It's 'all systems go' as ReNeuron gears up for Phase III stroke disability study

ReNeuron will present the data to the American Society for Exosomes and Microvesicles (ASEMV) 2017 meeting currently underway in San Francisco.

Exosomes are nano-sized particles in the bloodstream and other body fluids that can be absorbed by other cells.

New research, including by ReNeuron, points to them having a major impact on the way cells behave with a number of advantages in therapeutic treatments, in particular that they can be engineered to be strong and targeted delivery mechanisms.

ReNeuron has extended cash runway as it focuses on validating its exosome...

ReNeuron Group PLC (AIM:RENE, OTC:RNUGF) executive chairman Iain Ross tells Proactive that the company is focused on generating in vivo data and validating its exosome delivery technology platform CustomEX as 2023 gets underway. ReNeuron will conduct head-to-head studies with its competitors...

on 17/2/23